Casdin Capital, Llc Acquires 150,000 Shares of GeneDx (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) Director Casdin Capital, Llc acquired 150,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was acquired at an average price of $56.44 per share, with a total value of $8,466,000.00. Following the purchase, the director owned 3,657,164 shares in the company, valued at approximately $206,410,336.16. This represents a 4.28% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Casdin Capital, Llc also recently made the following trade(s):

• On Friday, June 5th, Casdin Capital, Llc acquired 50,000 shares of GeneDx stock. The stock was acquired at an average price of $52.86 per share, with a total value of $2,643,000.00.
• On Wednesday, May 20th, Casdin Capital, Llc acquired 140,000 shares of GeneDx stock. The stock was acquired at an average price of $43.81 per share, with a total value of $6,133,400.00.
• On Tuesday, May 19th, Casdin Capital, Llc acquired 185,000 shares of GeneDx stock. The stock was acquired at an average price of $42.60 per share, with a total value of $7,881,000.00.
• On Monday, May 18th, Casdin Capital, Llc acquired 175,000 shares of GeneDx stock. The stock was acquired at an average price of $42.55 per share, with a total value of $7,446,250.00.

GeneDx Trading Up 8.7%

Shares of WGS stock opened at $56.33 on Wednesday. GeneDx Holdings Corp. has a 52-week low of $32.21 and a 52-week high of $170.87. The stock has a market cap of $1.67 billion, a price-to-earnings ratio of -21.02 and a beta of 1.96. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The firm has a fifty day moving average of $55.24 and a 200-day moving average of $91.57.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. The business had revenue of $102.25 million during the quarter, compared to analyst estimates of $112.46 million. During the same quarter in the prior year, the company posted ($0.23) EPS. On average, equities research analysts forecast that GeneDx Holdings Corp. will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeneDx

A number of hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its position in shares of GeneDx by 4.5% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,220,502 shares of the company’s stock worth $158,738,000 after purchasing an additional 52,322 shares in the last quarter. Vanguard Group Inc. grew its holdings in GeneDx by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 1,189,069 shares of the company’s stock worth $154,650,000 after acquiring an additional 18,647 shares during the last quarter. Franklin Resources Inc. grew its holdings in GeneDx by 60.4% during the 4th quarter. Franklin Resources Inc. now owns 1,092,988 shares of the company’s stock worth $142,154,000 after acquiring an additional 411,607 shares during the last quarter. Westfield Capital Management Co. LP grew its holdings in GeneDx by 87.1% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,018,261 shares of the company’s stock worth $132,435,000 after acquiring an additional 474,167 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in GeneDx by 59.2% during the 4th quarter. Invesco Ltd. now owns 786,466 shares of the company’s stock worth $102,288,000 after acquiring an additional 292,394 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

Key Stories Impacting GeneDx

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Director Casdin Capital, LLC bought 50,000 shares at an average price of $52.86, adding to a recent buying streak that may signal confidence from a major insider. SEC filing
• Positive Sentiment: Casdin Capital also disclosed a larger purchase of 150,000 shares at $56.44 on June 4, reinforcing the impression of insider accumulation after the stock’s recent weakness. SEC filing
• Neutral Sentiment: GeneDx also presented at Goldman Sachs’ Global Healthcare Conference, which may have helped keep the stock in focus, but no major new operating update was highlighted in the transcript. Conference transcript
• Neutral Sentiment: Analyst sentiment remains mixed-to-positive overall, with the stock carrying an average “Moderate Buy” rating, though that view has not changed the near-term legal headline risk. Analyst rating update
• Negative Sentiment: Several law firms issued fresh class-action notices and lead-plaintiff reminders tied to GeneDx’s stock drop after its Q1 results, keeping investor attention on potential securities-fraud claims and litigation uncertainty. Class action alert
• Negative Sentiment: The lawsuits center on alleged misleading disclosures and a steep post-earnings selloff, which may continue to weigh on sentiment despite insider buying. Litigation report

Analyst Ratings Changes

WGS has been the subject of a number of recent research reports. Guggenheim dropped their price objective on shares of GeneDx from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. BTIG Research dropped their target price on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research report on Tuesday, May 5th. Jefferies Financial Group set a $150.00 target price on shares of GeneDx in a research report on Monday, February 23rd. Craig Hallum reiterated a “buy” rating and set a $85.00 target price on shares of GeneDx in a research report on Tuesday, May 5th. Finally, Wells Fargo & Company reiterated an “overweight” rating and set a $75.00 target price (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, GeneDx has a consensus rating of “Moderate Buy” and a consensus target price of $96.43.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.